Furthermore, a larger meta-analysis of more than 100 RCTs and with no racial or ethnic restrictions showed that the risk of UTI was similar between SGLT2 inhibitors and a placebo38. This evidence concerns the gene SLC5A2 and bacterial urinary tract infection.